Výsledky vyhľadávania - "Anti-Obesity Agents adverse effects"

Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis

Autori: Balata, Mahmoud Becher, Marc Ulrich

Zdroj: BMC Cardiovasc Disord
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-10 (2024)

Predmety: Male, Time Factors, Weight reduction, Glucagon-Like Peptides, Heart failure, Body Mass Index, Weight Loss, Diseases of the circulatory (Cardiovascular) system, Humans, Obesity, Propensity Score, Retrospective Studies, Aged, Heart Failure, Research, Semaglutide, Recovery of Function, Middle Aged, Aged [MeSH], Glucagon-Like Peptides/adverse effects [MeSH], Obesity/diagnosis [MeSH], Male [MeSH], Obesity/physiopathology [MeSH], Obesity/blood [MeSH], Propensity Score [MeSH], Weight Loss/drug effects [MeSH], Female [MeSH], Recovery of Function [MeSH], Glucagon-Like Peptide-1 Receptor/agonists [MeSH], Heart Failure/drug therapy [MeSH], Heart Failure/physiopathology [MeSH], Humans [MeSH], Anti-Obesity Agents/adverse effects [MeSH], Treatment Outcome [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Obesity/drug therapy [MeSH], Time Factors [MeSH], Obesity/complications [MeSH], Body Mass Index [MeSH], Glucagon-like peptide 1 receptor agonist, Glucagon-Like Peptides/therapeutic use [MeSH], Anti-Obesity Agents/therapeutic use [MeSH], Functional Status [MeSH], Heart Failure/diagnosis [MeSH], Treatment Outcome, Functional Status, Glucagon-Like Peptide-1 Receptor Agonists, RC666-701, Female, Anti-Obesity Agents

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39462311
https://doaj.org/article/78c6c558cc3a4a8a977cc08ef214cfc7
https://repository.publisso.de/resource/frl:6522571

Compléments alimentaires pour la perte de poids : revue de leur efficacité et sécurité

Autori: Monney, Marine Pataky, Zoltan Correia, Jorge

Zdroj: Revue Médicale Suisse. 18:527-530

Predmety: 03 medical and health sciences, 0302 clinical medicine, Dietary Supplements, Weight Loss, Anti-Obesity Agents / adverse effects, Prevalence, Humans, Obesity / drug therapy, Obesity / epidemiology

Popis súboru: application/pdf

Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions.

Autori: Cruz-Hernandez, C. Destaillats, F. Thakkar, S.K. a ďalší

Predmety: Adult, Anti-Obesity Agents/adverse effects, Anti-Obesity Agents/therapeutic use, Cell Membrane/metabolism, Chylomicrons, Docosahexaenoic Acids/administration & dosage, Docosahexaenoic Acids/pharmacokinetics, Double-Blind Method, Eicosapentaenoic Acid/administration & dosage, Eicosapentaenoic Acid/pharmacokinetics, Erythrocytes/metabolism, Female, Fish Oils/administration & dosage, Fish Oils/pharmacokinetics, Humans, Lactones/adverse effects, Lactones/therapeutic use, Lipid Metabolism Disorders/chemically induced, Lipid Metabolism Disorders/drug therapy, Male, Middle Aged, Monoglycerides/administration & dosage, Obesity/blood, Obesity/drug therapy, Orlistat, clinical trials, diet effects/lipid metabolism, digestion, docosahexaenoic acid, eicosapentaenoic acid

Relation: Journal of Lipid Research; https://iris.unil.ch/handle/iris/234201; serval:BIB_FC952A3307AC; 000389473000012

Dostupnosť: https://iris.unil.ch/handle/iris/234201
https://doi.org/10.1194/jlr.P070144

Effect of immediate and prolonged GLP‐1 receptor agonist administration on uric acid and kidney clearance: Post‐hoc analyses of four clinical trials

Autori: Lennart Tonneijck Marcel H. A. Muskiet Mark M. Smits a ďalší

Prispievatelia: Lennart Tonneijck Marcel H. A. Muskiet Mark M. Smits a ďalší

Zdroj: Tonneijck, L, Muskiet, M H A, Smits, M M, Bjornstad, P, Kramer, M H H, Diamant, M, Hoorn, E J, Joles, J A & van Raalte, D H 2018, 'Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials', Diabetes, Obesity and Metabolism, vol. 20, no. 5, pp. 1235-1245. https://doi.org/10.1111/dom.13223

Predmety: Male, Endocrinology, Diabetes and Metabolism, Anti-Obesity Agents/adverse effects, Kidney/drug effects, Kidney, Overweight/complications, Hypoglycemic Agents/adverse effects, Body Mass Index, Endocrinology, 0302 clinical medicine, Peptides/adverse effects, Glucagon-Like Peptide-1 Receptor/agonists, Insulin, Diabetic Nephropathies, Renal Insufficiency, EMC MM-04-39-10, liraglutide, Diabetic Nephropathies/chemically induced, Research Support, Non-U.S. Gov't, Middle Aged, 6. Clean water, Insulin/adverse effects, Randomized Controlled Trial, Female, type 2 diabetes, Adult, exenatide, Weight Loss/drug effects, Glucagon-Like Peptide-1 Receptor, Uric Acid/blood, Young Adult, 03 medical and health sciences, Journal Article, Internal Medicine, Humans, Hypoglycemic Agents, Comparative Study, Obesity, Aged, Renal Insufficiency/chemically induced, diabetic nephropathy, Diabetes Mellitus, Type 2/complications, Overweight, randomised trial, Uric Acid, Renal Elimination, Renal Elimination/drug effects, Diabetes Mellitus, Type 2, Anti-Obesity Agents, Obesity/complications, GLP-1, Peptides

Popis súboru: application/pdf

Prístupová URL adresa: https://europepmc.org/articles/pmc5899927?pdf=render
https://pubmed.ncbi.nlm.nih.gov/29341461
https://pure.eur.nl/en/publications/e977774b-780e-48b6-903e-75e6736880ed
https://doi.org/10.1111/dom.13223
https://www.ncbi.nlm.nih.gov/pubmed/29341461
https://dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.1111/dom.13223
https://europepmc.org/article/MED/29341461
https://onlinelibrary.wiley.com/doi/10.1111/dom.13223
https://pubmed.ncbi.nlm.nih.gov/29341461/
https://repub.eur.nl/pub/112837
https://research.vumc.nl/en/publications/848f7943-e495-4cc0-a4a0-ca4341bc3ae2
https://dspace.library.uu.nl/handle/1874/457283

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

Autori: Cecilie Heerdegen Jepsen Lars Endahl Tine W. Hansen a ďalší

Zdroj: von Scholten, B J, Davies, M J, Persson, F, Hansen, T W, Madsbad, S, Endahl, L, Jepsen, C H & Rossing, P 2017, 'Effect of weight reductions on estimated kidney function : Post-hoc analysis of two randomized trials', Journal of Diabetes and its Complications, vol. 31, no. 7, pp. 1164-1168. https://doi.org/10.1016/j.jdiacomp.2017.04.003

Predmety: Adult, Male, Prediabetic State/blood, Weight Loss/drug effects, Anti-Obesity Agents/adverse effects, Kidney/drug effects, Kidney, Glomerular Filtration Rate/drug effects, Glycated Hemoglobin A/analysis, Hypoglycemic Agents/adverse effects, Body Mass Index, Prediabetic State, 03 medical and health sciences, Kidney function, 0302 clinical medicine, Double-Blind Method, Diabetes Mellitus, Liraglutide/adverse effects, Humans, Hypoglycemic Agents, Diabetic Nephropathies, Estimated glomerular filtration rate, Obesity, Combined Modality Therapy/adverse effects, Type 2/blood, Glycated Hemoglobin, 2. Zero hunger, Renal Insufficiency/chemically induced, Diabetic Nephropathies/chemically induced, Creatinine/blood, Liraglutide, Middle Aged, Combined Modality Therapy, 3. Good health, Serum creatinine, Diabetes Mellitus, Type 2, Creatinine, Female, Anti-Obesity Agents, Obesity/complications, Biomarkers/blood, Biomarkers, Glomerular Filtration Rate

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/28462892
https://pubmed.ncbi.nlm.nih.gov/28462892/
https://www.sciencedirect.com/science/article/pii/S1056872717302805
https://www.ncbi.nlm.nih.gov/pubmed/28462892

Drugs against overweight - more important to focus on lifestyle changes? / Legemidler mot overvekt – viktigere å fokusere på livsstilsendringer?

Autori: Norvik, Mari Fleiner, Hanne Fiskvik

Zdroj: Utposten. 48(7):62

Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance: Post-marketing experiences from the EU adverse event reporting system EudraVigilance

Autori: Aagaard, L Hallgreen, C E Hansen, E H

Zdroj: Aagaard, L, Hallgreen, C E & Hansen, E H 2016, ' Serious adverse events reported for anti-obesity medicines : Post-marketing experiences from the EU adverse event reporting system EudraVigilance ', International Journal of Obesity, vol. 40, no. 11, pp. 1742-1747 . https://doi.org/10.1038/ijo.2016.135

Predmety: Adult, Male, Adolescent, Databases, Factual, Drug-Related Side Effects and Adverse Reactions, Obesity/drug therapy, Denmark, Anti-Obesity Agents/adverse effects, Psychoses, Substance-Induced, Drug-Related Side Effects and Adverse Reactions/epidemiology, Databases, Pharmacovigilance, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Adverse Drug Reaction Reporting Systems, Humans, Obesity, Child, Factual, Retrospective Studies, Substance-Induced/epidemiology, Community Participation, Psychoses, Middle Aged, Cardiovascular Diseases/chemically induced, Denmark/epidemiology, 3. Good health, Psychoses, Substance-Induced/epidemiology, Cardiovascular Diseases, Female, Anti-Obesity Agents

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/27478924
https://pubmed.ncbi.nlm.nih.gov/27478924/
https://core.ac.uk/display/50717433
https://www.ncbi.nlm.nih.gov/pubmed/27478924
https://portal.findresearcher.sdu.dk/da/publications/serious-adverse-events-reported-for-anti-obesity-medicines-post-m
https://www.nature.com/articles/ijo2016135.pdf
https://www.nature.com/articles/ijo2016135
https://portal.findresearcher.sdu.dk/da/publications/9e1ea805-fa03-4e26-aa34-772c6f0896f4

Pharmacotherapy for obesity

Autori: Cheung, BMY Li, M

Zdroj: British Journal of Clinical Pharmacology. 68:804-810

Predmety: Lipase - antagonists and inhibitors, Time Factors, Body Mass Index, Lactones, 03 medical and health sciences, 0302 clinical medicine, Meta-Analysis as Topic, Piperidines, Appetite Depressants, Sibutramine, Humans, Obesity, Anti-Obesity Agents - adverse effects - pharmacology, Obesity - drug therapy - metabolism, Lactones - adverse effects - pharmacology, Orlistat, 2. Zero hunger, Clinical Trials as Topic, Anti-obesity drugs, Dose-Response Relationship, Drug, Body Weight, Lipase, 3. Good health, Pyrazoles, Anti-Obesity Agents, Rimonabant, Piperidines - adverse effects - pharmacology

Prístupová URL adresa: https://europepmc.org/articles/pmc2810792?pdf=render
https://pubmed.ncbi.nlm.nih.gov/20002075
https://sigmapubs.onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2009.03453.x
https://www.ncbi.nlm.nih.gov/pubmed/20002075
https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2125.2009.03453.x
https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2125.2009.03453.x
http://hub.hku.hk/handle/10722/91674
https://pubmed.ncbi.nlm.nih.gov/20002075/
http://hdl.handle.net/10722/91674

CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant

Autori: Scheen, André

Zdroj: Journal of Neuroendocrinology. 20:139-146

Predmety: 0301 basic medicine, Pyrazoles/adverse effects/therapeutic use, Diabetes Mellitus, Type 2/drug therapy, Obesity/drug therapy, Hypoglycemic Agents/therapeutic use, Systèmes cardiovasculaire & respiratoire, Sciences de la santé humaine, 03 medical and health sciences, Endocrinology, metabolism & nutrition, Piperidines, Receptor, Cannabinoid, CB1, Risk Factors, Cardiovascular & respiratory systems, Humans, Hypoglycemic Agents, Metformin/therapeutic use, Obesity, Anti-Obesity Agents/adverse effects/therapeutic use, Cardiovascular Diseases/etiology, Human health sciences, Metabolic Syndrome, Clinical Trials as Topic, Metabolic Syndrome X/etiology, Receptor, Cannabinoid, CB1/antagonists & inhibitors/physiology, Metformin, 3. Good health, Treatment Outcome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Pyrazoles, Anti-Obesity Agents, Rimonabant, Piperidines/adverse effects/therapeutic use, Algorithms, Endocrinologie, métabolisme & nutrition

Prístupová URL adresa: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2826.2008.01681.x
https://pubmed.ncbi.nlm.nih.gov/18426513
https://europepmc.org/article/MED/18426513
https://pubmed.ncbi.nlm.nih.gov/18426513/
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01681.x
http://orbi.ulg.ac.be/bitstream/2268/4256/1/CB1%20Receptor%20Blockade%20and%20its%20Impact_ocr.pdf
https://orbi.uliege.be/handle/2268/4256
https://www.ncbi.nlm.nih.gov/pubmed/18426513

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

Autori: Van Gaal, Luc F Scheen, André Rissanen, Aila M a ďalší

Prispievatelia: Van Gaal, Luc F Scheen, André Rissanen, Aila M a ďalší

Zdroj: European heart journal

Predmety: Adult, Blood Glucose, Male, 0301 basic medicine, Pyrazoles/adverse effects/therapeutic use, Weight Loss/drug effects, Sciences de la santé humaine, Obesity/blood/drug therapy/physiopathology, Body Mass Index, 03 medical and health sciences, Endocrinology, metabolism & nutrition, Piperidines, Receptors, Cannabinoid/antagonists & inhibitors, Humans, Insulin, Obesity, Anti-Obesity Agents/adverse effects/therapeutic use, Human health sciences, Cannabinoid Receptor Antagonists, Metabolic Syndrome, Cholesterol, HDL/blood, 0303 health sciences, Blood Glucose/metabolism, Dose-Response Relationship, Drug, Cholesterol, HDL, Middle Aged, Metabolic Syndrome X/prevention & control, 3. Good health, Triglycerides/blood, Treatment Outcome, Cardiovascular Diseases, Cardiovascular Diseases/etiology/prevention & control, Pyrazoles, Female, Human medicine, Anti-Obesity Agents, Rimonabant, Insulin/blood, Epidemiologic Methods, Piperidines/adverse effects/therapeutic use, Endocrinologie, métabolisme & nutrition

Prístupová URL adresa: https://academic.oup.com/eurheartj/article-pdf/29/14/1761/17048330/ehn076.pdf
https://pubmed.ncbi.nlm.nih.gov/18417461
https://core.ac.uk/display/13319491
http://orbi.ulg.ac.be/handle/2268/4246
https://europepmc.org/article/MED/18417461
https://academic.oup.com/eurheartj/article/29/14/1761/498074
https://orbi.uliege.be/handle/2268/4246
https://www.ncbi.nlm.nih.gov/pubmed/18417461
https://hdl.handle.net/2268/4246
https://doi.org/10.1093/eurheartj/ehn076
https://hdl.handle.net/10067/764410151162165141

Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review

Autori: Filippatos, T. D. Derdemezis, C. S. Gazi, I. F. a ďalší

Zdroj: Drug Safety. 31:53-65

Predmety: Orlistat, 0301 basic medicine, 0303 health sciences, Nonprescription Drugs, Lipase, Lactones/*adverse effects/therapeutic use, 3. Good health, Intestines, Lactones, 03 medical and health sciences, Intestines/drug effects/enzymology, Humans, Lipase/antagonists & inhibitors, Nonprescription Drugs/adverse effects/therapeutic use, Drug Interactions, Anti-Obesity Agents, Anti-Obesity Agents/adverse effects/therapeutic use

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/18095746
http://olympias.lib.uoi.gr/jspui/handle/123456789/19575

Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Autori: Toplak, H. Hamann, A. Moore, R. a ďalší

Zdroj: International Journal of Obesity. 31:138-146

Predmety: Adult, Blood Glucose, Male, Blood pressure - physiology, Double-blind method, Adolescent, Fructose - analogs & derivatives, Blood Pressure, Fructose, Drug Administration Schedule, 03 medical and health sciences, Diabetes mellitus, 0302 clinical medicine, Anti-obesity agents - adverse effects, Double-Blind Method, Blood glucose - analysis, Topiramate, Anti-obesity agents - therapeutic use, Humans, Hypoglycemic Agents, Obesity, Hypoglycemic agents - adverse effects, Treatment outcome, Middle aged, Hypoglycemic agents - therapeutic use, Aged, combination, Glycated Hemoglobin, 2. Zero hunger, Weight loss - drug effects, Drug administration schedule, Obesity - complications, Middle Aged, Metformin, 3. Good health, Diabetes Mellitus, Type 2, type 2 - complications, Metformin - adverse effects, Fructose - therapeutic use, Obesity - drug therapy, Drug Therapy, Combination, Female, Drug therapy, Anti-Obesity Agents, Metformin - therapeutic use, Glycated hemoglobin A - analysis, Fructose - adverse effects

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/16703004
https://www.nature.com/articles/0803382.pdf
https://www.ncbi.nlm.nih.gov/pubmed/16703004
https://europepmc.org/article/MED/16703004
https://pubmed.ncbi.nlm.nih.gov/16703004/
https://www.nature.com/articles/0803382

Drugs for weight loss treatment of obesity / Laegemidler til vaegttabsbehandling af fedme

Autori: Madsbad, Sten Astrup, Arbe

Zdroj: Månedsskrift for Almen Praksis. 94(2):153

Serious complications to a weight loss programme with HCG / Alvorlig komplikation i forbindelse med slankekur med humant choriongonadotropin

Autori: Thellesen, Line Jörgensen, Louise Von Halling Regeur, Jakob a ďalší

Zdroj: Ugeskrift for Laeger. 176(15):1410

Weight loss pills purchased on the Internet as the cause of ventricular fibrillation / Slankepiller köbt på internettet som årsag til ventrikelflimren

Autori: Pareek, Manan Lederballe Pedersen, Rasmus Leren, Trond Paul a ďalší

Zdroj: Ugeskrift for Laeger. 175(11):739

Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose

Autori: Muniz Martinez, Marie Carmen Nortier, Joëlle Vereerstraeten, Pierre a ďalší

Zdroj: Nephrology Dialysis Transplantation. 17:408-412

Predmety: Adult, Male, 0301 basic medicine, Chinese Herbal -- administration & dosage, Dose-Response Relationship, Kidney Failure, Homéopathie, 03 medical and health sciences, Autres spécialisations médicales et paramédicales, Risk Factors, Chronic -- physiopathology, Humans, Retrospective Studies, 0303 health sciences, Néphrologie - urologie, Dose-Response Relationship, Drug, Chinese Herbal -- adverse effects, Drugs, Chronic -- chemically induced, Aristolochia, Middle Aged, Anti-Obesity Agents -- adverse effects, 3. Good health, Aristolochia -- adverse effects, Kidney Failure, Chronic, Female, Anti-Obesity Agents, Drug, Anti-Obesity Agents -- administration & dosage, Drugs, Chinese Herbal

Popis súboru: 1 full-text file(s): application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/11865085
http://www.pkdiet.com/pdf/aristolochiaNephropathy.pdf
https://www.ncbi.nlm.nih.gov/pubmed/11865085
https://europepmc.org/abstract/MED/11865085
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/99038/Details
https://paperity.org/p/54160138/progression-rate-of-chinese-herb-nephropathy-impact-of-aristolochia-fangchi-ingested-dose
https://dial.uclouvain.be/pr/boreal/object/boreal:41637

Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss

Autori: Thomas Trouillot Daniel G Pace Roberto Guerciolini a ďalší

Zdroj: The American Journal of Gastroenterology. 96:1888-1894

Predmety: Adult, Male, 2. Zero hunger, Obesity - Drug Therapy - Metabolism, Bile - Chemistry, Anti-Obesity Agents - Adverse Effects - Pharmacokinetics - Pharmacology, Lactones - Adverse Effects - Pharmacokinetics - Pharmacology, Gallbladder - Drug Effects - Physiology, Middle Aged, Bile Acids And Salts - Chemistry, Cholesterol - Metabolism, 3. Good health, Enzyme Inhibitors - Adverse Effects - Pharmacokinetics - Pharmacology, Double-Blind Method, Weight Loss, Humans, Female, Lipase - Antagonists & Inhibitors, Lipids - Analysis, Energy Intake

Prístupová URL adresa: http://hub.hku.hk/handle/10722/148227
http://hdl.handle.net/10722/148227

Urothelial Carcinoma Associated with the Use of a Chinese Herb (Aristolochia fangchi)

Autori: Nortier, J L Martinez, M C Schmeiser, H H a ďalší

Zdroj: The New England journal of medicine, 342 (23

Predmety: Male, 0301 basic medicine, Urothelium -- pathology, Kidney, Carcinogens -- adverse effects, Kidney Failure, DNA Adducts, Autres spécialisations médicales et paramédicales, Carcinogens -- metabolism, Risk Factors, Drugs, Chinese Herbal -- adverse effects, Prevalence, Kidney Failure, Chronic -- pathology, 0303 health sciences, Néphrologie - urologie, Phenanthrenes -- analysis, Drugs, Middle Aged, Ochratoxins, Ureter -- pathology, 3. Good health, Chronic -- therapy, Phenanthrenes -- metabolism, Kidney Failure, Chronic -- chemically induced, Aristolochic Acids, Female, Drug, Urologic Neoplasms, Phenanthrenes -- adverse effects, Urologic Neoplasms -- chemically induced, Dose-Response Relationship, Homéopathie, 03 medical and health sciences, DNA Adducts -- analysis, Chronic -- pathology, Urologic Neoplasms -- pathology, Humans, Carcinogens -- analysis, Ochratoxins -- analysis, Dose-Response Relationship, Drug, Chinese Herbal -- adverse effects, Chronic -- chemically induced, Phenanthrenes, Kidney Failure, Chronic -- therapy, Anti-Obesity Agents -- adverse effects, Cancérologie, Carcinogens, Kidney Failure, Chronic, Anti-Obesity Agents, Ureter, Urothelium, Kidney -- pathology, Drugs, Chinese Herbal

Popis súboru: 1 full-text file(s): application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/10841870
https://www.nejm.org/doi/10.1056/NEJM200006083422301
https://www.nejm.org/doi/abs/10.1056/NEJM200006083422301
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/15229/Holdings
https://www.cabdirect.org/abstracts/20000311884.html
https://www.ncbi.nlm.nih.gov/pubmed/10841870
https://europepmc.org/article/MED/10841870
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/15229

Picture of the month: coronary arteriosclerosis / Månedens billede

Autori: Horskaer Madsen, Stine Bayer Kristensen, Ingrid Rosendal, Ingrid

Zdroj: Ugeskrift for Laeger. 172(12):971

Reported psychiatric adverse effects of Acomplia - a survey / Rapporterade psykiatriska biverkningar av Acomplia - en genomgång

Autori: AnonymouS

Zdroj: Information från Läkemedelsverket. 19(3):73